Formulary Search Results for: RUXOLITINIB
8.1.5 Other antineoplastic drugs - View Category
Total Formulary

RUXOLITINIB (JAKAVI) (tablets)
Restrictions:
Restricted to specialist use for the following indications:
- The treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, in accordance with regional protocols [NHS network access required].
- The treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea (hydroxycarbamide) in accordance with regional protocols [NHS network access required].
- Treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids.
Prescribing Notes:
The following indications are not recommended by SMC and remain non-formulary (approval via IPTR process):
- patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids
- ruxolitinib cream (Opzelura®) for the treatment of non-segmental vitiligo with facial involvement